Covidien plc (COV) recently announced the receipt of CE Mark approval for its Nellcor Bedside SpO2 Patient Monitoring System (PM100N). It the only commercially available bedside pulse oximetry (SpO2) monitor, currently available in the European Economic Area (EEA), Australia and New Zealand.
The Nellcor Bedside SpO2 Patient Monitoring System provides clinicians with access to real-time patient respiratory status information including continuous SpO2, pulse rate monitoring and trending data. This allows clinicians to evaluate a patient's clinical course and detect and respond to dangerous respiratory events sooner.
The system also incorporates the latest Nellcor digital signal processing technology for accurate, reliable readings even during low perfusion, motion, and other forms of signal interference, as well as SatSeconds alarm management to help distinguish meaningful alarms from transient events.
Featuring home care and sleep study modes that are complaint with standards for medical electrical equipment used in the home health care environment, Covidien’s latest system has functionality for non-hospital settings. The monitor can also be password-protected to ensure safe utilization by non-clinical users.
Covidien’s shares are up roughly 1% since the announcement, based on last Friday’s close of $98.44. The stock has delivered a healthy year-to-date return of around 47%
Covidien’s oximetry and monitoring products portfolio feature a number of Nellcor devices and technology including the Portable SpO2 Patient Monitoring System, Bedside Respiratory Patient Monitoring System, Respiration Rate Software and OxiMax Technology, among others.
Last month, Covidien received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Nellcor Portable SpO2 Patient Monitoring System (PM10N). The portable Patient Monitoring System is capable of accurate, quick and motion-tolerant monitoring of pulse rate and SpO2 owing to its compact and lightweight design. It is an ideal tool for multiple clinical screenings including: Six Minute Walk Test, Critical Congenital Heart Disease Screening and Car Seat Challenge Test.
In Jun 2014, Covidien secured CE Mark approval for the commercial launch of its Nellcor Respiration Rate System in the EU. Compared to currently available methods, Covidien’s Nellcor respiratory system is accurate, easy to use and may enable earlier medical intervention in case of a respiratory compromise.
Covidien’s Nellcor technology supports the company’s goal of becoming the front-runner in cutting-edge medical technology that enables clinicians to provide better patient care in all settings.
Currently, Covidien carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical products industry include GW Pharmaceuticals (GWPH), ICU Medical (ICUI) and OraSure Technologies (OSUR). All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment